DURHAM, N.C., April 2, 2026
restor3d, Inc., a leader in 3D-printed orthopedic medical devices, announced the full commercial release of its Aeros™ Modular Stem System in the United States, marking a significant advancement in total ankle replacement technology. The system, which follows a successful limited market release with over 250 procedures performed by more than 50 surgeons, introduces a novel anteriorly inserted modular stem implant designed to improve stability, preserve bone, and enhance surgical efficiency, setting a new benchmark in personalized orthopedic care.
Innovative Modular Design Enhances Surgical Precision
The Aeros™ Modular Stem System is the first and only modular stem ankle implant designed for anterior insertion, allowing surgeons to perform procedures using a standard surgical approach without bulky external hardware or disruption to surrounding joints. This innovative design enables enhanced implant fixation while minimizing surgical morbidity, addressing a longstanding challenge in ankle replacement procedures.
The system offers interchangeable articulation constructs, allowing surgeons to customize implant configurations based on patient anatomy and surgical preference, thereby improving procedural flexibility and clinical outcomes. This advancement supports more consistent and reproducible surgical workflows, reducing variability and enhancing overall treatment success.
3D-Printed Technology Supports Long-Term Osseointegration
Advertisement
Built on restor3d’s proprietary TIDAL Technology™, the system incorporates 3D-printed tibial and talar implants with optimized porous architecture, designed to promote biological fixation and long-term osseointegration. This advanced material design enhances the integration of implants with surrounding bone tissue, reducing the risk of mechanical failure and improving implant longevity.
Clinical data referenced in the release indicate that stemmed tibial implants significantly reduce the likelihood of mechanical failure compared to traditional low-profile implants, reinforcing the system’s potential to deliver durable and reliable outcomes. The integration of advanced manufacturing technologies with clinical design represents a major step forward in orthopedic innovation, aligning with the growing trend toward personalized, data-driven medical solutions.
AI-Driven Platform Strengthens Biologic Development
A key differentiator of HLX319 is its integration of Henlius’ proprietary “mAb + enzyme” platform and AI-driven R&D technologies, including advanced computational modeling and mechanistic analysis. The company’s Henozye® hyaluronidase platform facilitates subcutaneous delivery of large-molecule biologics, enabling stable co-formulation of complex therapies. This platform supports enhanced drug dispersion, absorption, and formulation stability, significantly improving development efficiency compared to conventional methods. The use of AI-assisted drug development accelerates innovation while maintaining high standards in Chemistry, Manufacturing, and Controls (CMC), ensuring consistency, scalability, and regulatory compliance.
Streamlined Workflow Improves Efficiency and Patient Outcomes
The Aeros™ system is designed to simplify surgical procedures through a structured and intuitive workflow, enabling surgeons to achieve efficient and predictable outcomes. Its compatibility with patient-specific resection guides (Axiom PSR™) further enhances precision, allowing for accurate bone preparation and implant placement. The system’s bone-preserving approach, achieved through minimized resections, helps maintain structural integrity and supports faster recovery for patients.
Early feedback from surgeons highlights improved intra-operative workflow and positive patient recovery outcomes, underscoring the system’s clinical value. By reducing reliance on multiple instrument trays and simplifying surgical steps, the system also contributes to operational efficiency and cost reduction in healthcare settings.
Advancing MedTech Innovation in Orthopedic Surgery
The commercial launch of the Aeros™ Modular Stem System reflects broader trends in the medical device industry, where innovation is driven by personalization, advanced materials, and digital health integration. restor3d’s expertise in 3D printing, AI-based planning, and design automation positions the company at the forefront of next-generation musculoskeletal reconstruction technologies. From a regulatory and quality perspective, the system aligns with FDA device standards and quality system regulations, ensuring compliance with strict safety, performance, and manufacturing requirements. This launch reinforces restor3d’s commitment to delivering innovative solutions that improve patient outcomes while advancing surgical precision and efficiency, contributing to the evolution of modern orthopedic care.
Source: restor3d press release
